TAB1 Polyclonal Antibody, Invitrogen™

Description

Recommended positive controls: 293T, A431, HeLa, A375, GL261, C8D30. Predicted reactivity: Mouse (97%), Rat (95%), Pig (96%), Chicken (90%), Rhesus Monkey (100%). Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

TGF-beta-activated kinase 1 and MAP3K7-binding protein 1 (TAB1) is a regulator of the MAP kinase kinase kinase MAP3K7/TAK1, which is known to mediate various intracellular signaling pathways, such as those induced by TGF beta, interleukin 1, and WNT-1. TAB1 interacts and thus activates TAK1 kinase. It has been shown that the C-terminal portion of TAB1 is sufficient for binding and activation of TAK1, while a portion of the N-terminus acts as a dominant-negative inhibitor of TGF beta, suggesting that this protein may function as a mediator between TGF beta receptors and TAK1. It can also interact with and activate the mitogen-activated protein kinase 14 (MAPK14/p38alpha), and thus represents an alternative activation pathway, in addition to the MAPKK pathways, which contributes to the biological responses of MAPK14 to various stimuli.